Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Teresa Smith

Nurse Practitioner, Adult Health Warrensburg, MO Nurse Practitioner

NPI 1629610126 CMS profile 10881116

403 Burkarth Rd, Warrensburg, MO 64093

Open in the dashboard

General payments

$6,648

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Teresa Smith of Warrensburg, MO is reported in the CMS Open Payments database as having received $6,648 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $697 28
2024 General $1,099 56
2023 General $1,308 70
2022 General $1,563 86
2021 General $1,980 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Teresa Smith
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Teresa Smith were reported at $697. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Teresa Smith Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,980 $138 $43–$438 $132
2022 $1,563 $165 $54–$494 $149
2023 $1,308 $178 $61–$549 $160
2024 $1,099 $186 $62–$575 $164
2025 $697 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,564 62 payments
  2. Novartis Pharmaceuticals Corporation $764 63 payments
  3. Merck Sharp & Dohme Corporation $610 31 payments
  4. Boston Scientific Corporation $606 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $563 25 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $344 11 payments
  7. AstraZeneca Pharmaceuticals LP $308 13 payments
  8. Pfizer Inc. $286 17 payments
  9. Janssen Pharmaceuticals, Inc $258 14 payments
  10. iRhythm Technologies, Inc. $257 9 payments
  11. Other $1,089 57 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,637 326 payments
  2. Education $11 2 payments
Products named General payments · program years 2021–2025
  1. Repatha Cardiology $1,305 57 payments
  2. VERQUVO $700 36 payments
  3. JARDIANCE $488 21 payments
  4. LifeVest $344 11 payments
  5. ENTRESTO $307 26 payments
  6. LEQVIO $300 22 payments
  7. REPATHA Cardiovascular $259 5 payments
  8. XARELTO $258 14 payments
  9. ZIO XT Patch $257 9 payments
  10. VYNDAQEL $238 13 payments
  11. Other $3,002 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,677

Median for Nurse Practitioner: 389

Drug cost

$359,865

Median for Nurse Practitioner: $21,885

Branded share of claims

19.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 208 $202,013
Xarelto Rivaroxaban Brand 82 $85,174
Jardiance Empagliflozin Brand 22 $25,713
Entresto Sacubitril/Valsartan Brand 18 $19,537
Metoprolol Succinate Generic 370 $4,166
Flecainide Acetate Generic 75 $3,017
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 64 $1,661
Rosuvastatin Calcium Generic 127 $1,474
Losartan Potassium Generic 186 $1,400
Carvedilol Generic 166 $1,334

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$13,207

Medicare's payments for the services billed

Medicare patients

187

Average age 77

Services billed

235

89 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 50%
Atrial fibrillation 48%
Arthritis 48%
Heart failure 43%
Diabetes 40%
Chronic kidney disease 33%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $235
$235 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $99
$99 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $90
$90 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $60
$60 22 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $47
$47 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record